Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats

Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of veterinary pharmacology and therapeutics 2017-12, Vol.40 (6), p.e11
Hauptverfasser: Lebkowska-Wieruszewska, B, De Vito, V, Owen, H, Poapholatep, A, Giorgi, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 6
container_start_page e11
container_title Journal of veterinary pharmacology and therapeutics
container_volume 40
creator Lebkowska-Wieruszewska, B
De Vito, V
Owen, H
Poapholatep, A
Giorgi, M
description Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized cross-over design. Cats were assigned to two treatment groups and administered with 2 mg/kg of grapiprant (pure powder) through p.o. and i.v. administration. Blood samples were collected at preassigned times and analysed by a validated HPLC method. After both administrations, grapiprant concentrations were detectable in plasma for up to 24 hr in five of six animals. The critical parameters including clearance (173.2 ml hr  kg , range 120-326 ml hr  kg ) and volume of distribution (918 ml/kg, range 611-1608 ml/kg) were calculated from the i.v. group. The mean oral F% was low (39.6% range 31.5%-45.2%). If the assumption that the minimal effective concentration in dogs (164 ng/ml) applies in cats too, grapiprant orally administered at 2 mg/kg might be effective for 10 hr. Further studies are necessary to establish the minimal effective concentration in this animal species.
doi_str_mv 10.1111/jvp.12414
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_jvp_12414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28459136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c976-f1ed8099c58c10cc4aa515e49929d744096eb3ed2dfa2a7b5c928a93aeec70863</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqWw4AeQt0gktR0nsZcIlYJUiS66j6a2E9zmJdtU4iP4Z1wKzGYWc-6V5iB0S0lK48x3hzGljFN-hqY0K_KECZGfoymhnCRlKbIJuvJ-RwjJBKWXaMIEz2Ukp-hr_Q6uAzXsbW-CVR4PNW4cjHZ00IcHDNib1qhgDwYv1pjj0Q0-QNNCr22P18sFZtgZZcYwOBwj0Ay99cdkHYyLx66Z7xs8OGjjWWObHlIMurNHykGwQ-9xbFIQ_DW6qKH15uZ3z9DmebF5eklWb8vXp8dVomRZJDU1WhApVS4UJUpxgJzmhkvJpC45J7Iw28xopmtgUG5zJZkAmYExqiSiyGbo_lSr4i_emboane3AfVaUVEejVTRa_RiN7N2JHT-2ndH_5J_C7BvtLXKX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lebkowska-Wieruszewska, B ; De Vito, V ; Owen, H ; Poapholatep, A ; Giorgi, M</creator><creatorcontrib>Lebkowska-Wieruszewska, B ; De Vito, V ; Owen, H ; Poapholatep, A ; Giorgi, M</creatorcontrib><description>Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized cross-over design. Cats were assigned to two treatment groups and administered with 2 mg/kg of grapiprant (pure powder) through p.o. and i.v. administration. Blood samples were collected at preassigned times and analysed by a validated HPLC method. After both administrations, grapiprant concentrations were detectable in plasma for up to 24 hr in five of six animals. The critical parameters including clearance (173.2 ml hr  kg , range 120-326 ml hr  kg ) and volume of distribution (918 ml/kg, range 611-1608 ml/kg) were calculated from the i.v. group. The mean oral F% was low (39.6% range 31.5%-45.2%). If the assumption that the minimal effective concentration in dogs (164 ng/ml) applies in cats too, grapiprant orally administered at 2 mg/kg might be effective for 10 hr. Further studies are necessary to establish the minimal effective concentration in this animal species.</description><identifier>ISSN: 0140-7783</identifier><identifier>EISSN: 1365-2885</identifier><identifier>DOI: 10.1111/jvp.12414</identifier><identifier>PMID: 28459136</identifier><language>eng</language><publisher>England</publisher><subject>Administration, Oral ; Animals ; Cats ; Cross-Over Studies ; Injections, Intravenous - veterinary ; Male ; Receptors, Prostaglandin E, EP4 Subtype - antagonists &amp; inhibitors ; Sulfonylurea Compounds - administration &amp; dosage ; Sulfonylurea Compounds - blood ; Sulfonylurea Compounds - pharmacokinetics</subject><ispartof>Journal of veterinary pharmacology and therapeutics, 2017-12, Vol.40 (6), p.e11</ispartof><rights>2017 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c976-f1ed8099c58c10cc4aa515e49929d744096eb3ed2dfa2a7b5c928a93aeec70863</citedby><cites>FETCH-LOGICAL-c976-f1ed8099c58c10cc4aa515e49929d744096eb3ed2dfa2a7b5c928a93aeec70863</cites><orcidid>0000-0003-3657-4703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28459136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lebkowska-Wieruszewska, B</creatorcontrib><creatorcontrib>De Vito, V</creatorcontrib><creatorcontrib>Owen, H</creatorcontrib><creatorcontrib>Poapholatep, A</creatorcontrib><creatorcontrib>Giorgi, M</creatorcontrib><title>Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats</title><title>Journal of veterinary pharmacology and therapeutics</title><addtitle>J Vet Pharmacol Ther</addtitle><description>Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized cross-over design. Cats were assigned to two treatment groups and administered with 2 mg/kg of grapiprant (pure powder) through p.o. and i.v. administration. Blood samples were collected at preassigned times and analysed by a validated HPLC method. After both administrations, grapiprant concentrations were detectable in plasma for up to 24 hr in five of six animals. The critical parameters including clearance (173.2 ml hr  kg , range 120-326 ml hr  kg ) and volume of distribution (918 ml/kg, range 611-1608 ml/kg) were calculated from the i.v. group. The mean oral F% was low (39.6% range 31.5%-45.2%). If the assumption that the minimal effective concentration in dogs (164 ng/ml) applies in cats too, grapiprant orally administered at 2 mg/kg might be effective for 10 hr. Further studies are necessary to establish the minimal effective concentration in this animal species.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Cats</subject><subject>Cross-Over Studies</subject><subject>Injections, Intravenous - veterinary</subject><subject>Male</subject><subject>Receptors, Prostaglandin E, EP4 Subtype - antagonists &amp; inhibitors</subject><subject>Sulfonylurea Compounds - administration &amp; dosage</subject><subject>Sulfonylurea Compounds - blood</subject><subject>Sulfonylurea Compounds - pharmacokinetics</subject><issn>0140-7783</issn><issn>1365-2885</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRS0EoqWw4AeQt0gktR0nsZcIlYJUiS66j6a2E9zmJdtU4iP4Z1wKzGYWc-6V5iB0S0lK48x3hzGljFN-hqY0K_KECZGfoymhnCRlKbIJuvJ-RwjJBKWXaMIEz2Ukp-hr_Q6uAzXsbW-CVR4PNW4cjHZ00IcHDNib1qhgDwYv1pjj0Q0-QNNCr22P18sFZtgZZcYwOBwj0Ay99cdkHYyLx66Z7xs8OGjjWWObHlIMurNHykGwQ-9xbFIQ_DW6qKH15uZ3z9DmebF5eklWb8vXp8dVomRZJDU1WhApVS4UJUpxgJzmhkvJpC45J7Iw28xopmtgUG5zJZkAmYExqiSiyGbo_lSr4i_emboane3AfVaUVEejVTRa_RiN7N2JHT-2ndH_5J_C7BvtLXKX</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Lebkowska-Wieruszewska, B</creator><creator>De Vito, V</creator><creator>Owen, H</creator><creator>Poapholatep, A</creator><creator>Giorgi, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-3657-4703</orcidid></search><sort><creationdate>201712</creationdate><title>Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats</title><author>Lebkowska-Wieruszewska, B ; De Vito, V ; Owen, H ; Poapholatep, A ; Giorgi, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c976-f1ed8099c58c10cc4aa515e49929d744096eb3ed2dfa2a7b5c928a93aeec70863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Cats</topic><topic>Cross-Over Studies</topic><topic>Injections, Intravenous - veterinary</topic><topic>Male</topic><topic>Receptors, Prostaglandin E, EP4 Subtype - antagonists &amp; inhibitors</topic><topic>Sulfonylurea Compounds - administration &amp; dosage</topic><topic>Sulfonylurea Compounds - blood</topic><topic>Sulfonylurea Compounds - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lebkowska-Wieruszewska, B</creatorcontrib><creatorcontrib>De Vito, V</creatorcontrib><creatorcontrib>Owen, H</creatorcontrib><creatorcontrib>Poapholatep, A</creatorcontrib><creatorcontrib>Giorgi, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lebkowska-Wieruszewska, B</au><au>De Vito, V</au><au>Owen, H</au><au>Poapholatep, A</au><au>Giorgi, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats</atitle><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle><addtitle>J Vet Pharmacol Ther</addtitle><date>2017-12</date><risdate>2017</risdate><volume>40</volume><issue>6</issue><spage>e11</spage><pages>e11-</pages><issn>0140-7783</issn><eissn>1365-2885</eissn><abstract>Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized cross-over design. Cats were assigned to two treatment groups and administered with 2 mg/kg of grapiprant (pure powder) through p.o. and i.v. administration. Blood samples were collected at preassigned times and analysed by a validated HPLC method. After both administrations, grapiprant concentrations were detectable in plasma for up to 24 hr in five of six animals. The critical parameters including clearance (173.2 ml hr  kg , range 120-326 ml hr  kg ) and volume of distribution (918 ml/kg, range 611-1608 ml/kg) were calculated from the i.v. group. The mean oral F% was low (39.6% range 31.5%-45.2%). If the assumption that the minimal effective concentration in dogs (164 ng/ml) applies in cats too, grapiprant orally administered at 2 mg/kg might be effective for 10 hr. Further studies are necessary to establish the minimal effective concentration in this animal species.</abstract><cop>England</cop><pmid>28459136</pmid><doi>10.1111/jvp.12414</doi><orcidid>https://orcid.org/0000-0003-3657-4703</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0140-7783
ispartof Journal of veterinary pharmacology and therapeutics, 2017-12, Vol.40 (6), p.e11
issn 0140-7783
1365-2885
language eng
recordid cdi_crossref_primary_10_1111_jvp_12414
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Administration, Oral
Animals
Cats
Cross-Over Studies
Injections, Intravenous - veterinary
Male
Receptors, Prostaglandin E, EP4 Subtype - antagonists & inhibitors
Sulfonylurea Compounds - administration & dosage
Sulfonylurea Compounds - blood
Sulfonylurea Compounds - pharmacokinetics
title Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T00%3A42%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20grapiprant,%20a%20selective%20EP%204%20prostaglandin%20PGE%202%20receptor%20antagonist,%20after%202%20mg/kg%20oral%20and%20i.v.%20administrations%20in%20cats&rft.jtitle=Journal%20of%20veterinary%20pharmacology%20and%20therapeutics&rft.au=Lebkowska-Wieruszewska,%20B&rft.date=2017-12&rft.volume=40&rft.issue=6&rft.spage=e11&rft.pages=e11-&rft.issn=0140-7783&rft.eissn=1365-2885&rft_id=info:doi/10.1111/jvp.12414&rft_dat=%3Cpubmed_cross%3E28459136%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28459136&rfr_iscdi=true